S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
TSLA   547.20 (+7.19%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
DIS   143.54 (-0.55%)
GILD   62.65 (-0.52%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
TSLA   547.20 (+7.19%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
DIS   143.54 (-0.55%)
GILD   62.65 (-0.52%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
TSLA   547.20 (+7.19%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
DIS   143.54 (-0.55%)
GILD   62.65 (-0.52%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
TSLA   547.20 (+7.19%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
DIS   143.54 (-0.55%)
GILD   62.65 (-0.52%)
Log in

NASDAQ:STRO - Sutro Biopharma Stock Price, Forecast & News

$12.13
+0.18 (+1.51 %)
(As of 01/21/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.95
Now: $12.13▼
$12.33
50-Day Range
$9.95
MA: $11.21▼
$12.09
52-Week Range
$7.69
Now: $12.13▼
$12.75
Volume54,844 shs
Average Volume80,505 shs
Market Capitalization$280.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STRO
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://www.sutrobio.com/
Phone650-392-8412

Debt

Debt-to-Equity RatioN/A
Current Ratio3.78
Quick Ratio3.78

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.42 million
Price / Sales7.29
Cash FlowN/A
Price / Cash FlowN/A
Book Value($6.58) per share
Price / Book-1.84

Profitability

EPS (Most Recent Fiscal Year)($6.13)
Net Income$-35,320,000.00
Net Margins-84.03%
Return on EquityN/A
Return on Assets-21.60%

Miscellaneous

Employees141
Outstanding Shares23,090,000
Market Cap$280.08 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:STRO Rates by TradingView

(Ad)


Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma Inc (NASDAQ:STRO) posted its quarterly earnings results on Friday, November, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. The business had revenue of $12.28 million for the quarter, compared to analysts' expectations of $8.88 million. View Sutro Biopharma's Earnings History.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Sutro Biopharma.

What price target have analysts set for STRO?

7 analysts have issued 12 month price targets for Sutro Biopharma's stock. Their forecasts range from $16.00 to $22.00. On average, they expect Sutro Biopharma's share price to reach $19.17 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View Analyst Price Targets for Sutro Biopharma.

What is the consensus analysts' recommendation for Sutro Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma.

What are Wall Street analysts saying about Sutro Biopharma stock?

Here are some recent quotes from research analysts about Sutro Biopharma stock:
  • 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019)

Has Sutro Biopharma been receiving favorable news coverage?

Headlines about STRO stock have trended positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sutro Biopharma earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Sutro Biopharma.

Are investors shorting Sutro Biopharma?

Sutro Biopharma saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 45,200 shares, a drop of 69.0% from the December 15th total of 145,800 shares. Based on an average daily volume of 55,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the shares of the company are short sold. View Sutro Biopharma's Current Options Chain.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the folowing people:
  • Mr. William J. Newell, CEO & Director (Age 61)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
  • Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 61)

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $12.13.

How big of a company is Sutro Biopharma?

Sutro Biopharma has a market capitalization of $280.08 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.View Additional Information About Sutro Biopharma.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is http://www.sutrobio.com/.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.


MarketBeat Community Rating for Sutro Biopharma (NASDAQ STRO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote "Outperform" if you believe STRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Why do companies engage in swaps?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel